Yu Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yu Guo has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Wenmiao Luo
Department of Neurosurgery, Xiamen Susong Hospital, Xiamen, China
5 shared publications - Hengzhu Zhang
Northern Jiangsu People’s Hospital Affiliated to Yangzhou University, Yangzhou, China
4 shared publications Chao Liu
Department of Neurosurgery, Xiamen Susong Hospital, Xiamen, China
2 shared publicationsFangbao Li
Department of Neurosurgery Northern Jiangsu People's Hospital Affiliated to Yangzhou University Yangzhou Jiangsu People's Republic of China
2 shared publications- Mingfei Yang
Department of Neurosurgery, Qinghai Provincial People's Hospital
2 shared publications - Chao Liu
Department of Neurosurgery, Xiamen Susong Hospital, Xiamen, China
1 shared publication
Latest Publications
- 28 July 2026
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 18 (4) , e70071
Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives
Glioblastoma (GBM) remains one of the most aggressive primary brain tumors, with poor prognosis, high recurrence, and limited therapeutic options. Although substantial progress has been made in drug development, effective clinical translation is still constrained by inefficient delivery across the blood brain barrier (BBB) and blood brain tumor barrier (BBTB), insufficient tumor accumulation, intratumoral heterogeneity, acquired therapeutic resistance, and dose limiting systemic toxicity. Nanomedicine offers a promising strategy to address these barriers through tunable physicochemical properties, flexible surface functionalization, improved pharmacokinetics, and controllable drug release. In this review, we systematically summarize recent advances in nanomedicine enabled GBM therapy from four interrelated perspectives: the optimization of nanomaterial properties, the development of goal‐oriented targeting strategies, the rationalization of delivery routes, and the engineering of smart stimuli‐responsive nano‐systems. Rather than only cataloguing representative nanoplatforms, we emphasize how material parameters, biological targeting mechanisms, delivery routes, and release behaviors are mechanistically linked to BBB or BBTB penetration, tumor accumulation, therapeutic efficacy, and translational feasibility. Importantly, we also incorporate a key failure case analysis of representative clinical and preclinical studies, highlighting why promising nanotherapeutic concepts may fail because of inadequate intratumoral distribution, insufficient survival benefit, poor patient selection, manufacturing complexity, safety concerns, or impractical trial design. By integrating delivery mechanisms, cross platform comparison, translational barriers, and future optimization principles, this review provides a critical and forward looking framework for the rational design of precise, effective, and clinically translatable nanomedicine strategies for GBM treatment.
- 28 July 2026
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 18 (4) , e70071
Nanomedicine for Glioblastoma Therapy: Novel Insights and Future Perspectives
Glioblastoma (GBM) remains one of the most aggressive primary brain tumors, with poor prognosis, high recurrence, and limited therapeutic options. Although substantial progress has been made in drug development, effective clinical translation is still constrained by inefficient delivery across the blood brain barrier (BBB) and blood brain tumor barrier (BBTB), insufficient tumor accumulation, intratumoral heterogeneity, acquired therapeutic resistance, and dose limiting systemic toxicity. Nanomedicine offers a promising strategy to address these barriers through tunable physicochemical properties, flexible surface functionalization, improved pharmacokinetics, and controllable drug release. In this review, we systematically summarize recent advances in nanomedicine enabled GBM therapy from four interrelated perspectives: the optimization of nanomaterial properties, the development of goal‐oriented targeting strategies, the rationalization of delivery routes, and the engineering of smart stimuli‐responsive nano‐systems. Rather than only cataloguing representative nanoplatforms, we emphasize how material parameters, biological targeting mechanisms, delivery routes, and release behaviors are mechanistically linked to BBB or BBTB penetration, tumor accumulation, therapeutic efficacy, and translational feasibility. Importantly, we also incorporate a key failure case analysis of representative clinical and preclinical studies, highlighting why promising nanotherapeutic concepts may fail because of inadequate intratumoral distribution, insufficient survival benefit, poor patient selection, manufacturing complexity, safety concerns, or impractical trial design. By integrating delivery mechanisms, cross platform comparison, translational barriers, and future optimization principles, this review provides a critical and forward looking framework for the rational design of precise, effective, and clinically translatable nanomedicine strategies for GBM treatment.
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (3) , e251307
Therapeutic Efficacy of Endovascular Thrombectomy in Acute Basilar Artery Occlusion with Mild Symptoms
Compared with intravenous thrombolysis, endovascular thrombectomy was associated with a higher likelihood of excellent functional outcome in patients with basilar artery occlusion with National Institutes of Health Stroke Scale scores of 0–9.
- 1 December 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 317 (3) , e251307
Therapeutic Efficacy of Endovascular Thrombectomy in Acute Basilar Artery Occlusion with Mild Symptoms
Compared with intravenous thrombolysis, endovascular thrombectomy was associated with a higher likelihood of excellent functional outcome in patients with basilar artery occlusion with National Institutes of Health Stroke Scale scores of 0–9.
- Open Access
- 1 May 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 7061-7092
Carbon Dot-Based Nanoparticles: A Promising Therapeutic Approach for Glioblastoma
Glioblastoma (GBM) is a malignant tumor that currently still faces challenges for a complete cure. Although GBM treatment has made great progress, the prognosis of patients is still poor due to interference of various factors in treatment such as the blood-brain barrier (BBB), grade malignancy, intra- and intertumor heterogeneity, drug resistance, and poor targeting of anti-tumor drugs. In recent years, with marked advances in nanotechnology, different types of nanodrug delivery systems have been developed and have been considered as a promising therapeutic measure to gradually overcome chemotherapy resistance and improve tumor targeting. Carbon dots (CDs), as a new type of therapeutic NP, have become a research hotspot of concern for many researchers in recent years. NPs based on CDs have high modifiability and functionalization, allowing for covalent binding with chemotherapy drugs, genes, immune cells and photosensitizers, effectively targeting tumor cells and reducing peripheral cytotoxicity. However, at present, CDs are still in the basic research stage or the preclinical exploratory research stage, and has not yet entered the clinical trial stage or the implementation and application stage. Here, we review the fundamental principles of CDs in the broader field of nanotechnology, their development history, classification, synthesis, and potential for tumor treatment. Especially in the treatment of cancer, CDs can not only participate in photodynamic therapy, photothermal therapy, sonodynamic therapy, chemodynamic therapy, and chemotherapy, but also in multi-modal combination therapy. Here, we hope to provide some insights for further research.
- 1 May 2025
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 7061-7092
Open AccessCarbon Dot-Based Nanoparticles: A Promising Therapeutic Approach for Glioblastoma
Glioblastoma (GBM) is a malignant tumor that currently still faces challenges for a complete cure. Although GBM treatment has made great progress, the prognosis of patients is still poor due to interference of various factors in treatment such as the blood-brain barrier (BBB), grade malignancy, intra- and intertumor heterogeneity, drug resistance, and poor targeting of anti-tumor drugs. In recent years, with marked advances in nanotechnology, different types of nanodrug delivery systems have been developed and have been considered as a promising therapeutic measure to gradually overcome chemotherapy resistance and improve tumor targeting. Carbon dots (CDs), as a new type of therapeutic NP, have become a research hotspot of concern for many researchers in recent years. NPs based on CDs have high modifiability and functionalization, allowing for covalent binding with chemotherapy drugs, genes, immune cells and photosensitizers, effectively targeting tumor cells and reducing peripheral cytotoxicity. However, at present, CDs are still in the basic research stage or the preclinical exploratory research stage, and has not yet entered the clinical trial stage or the implementation and application stage. Here, we review the fundamental principles of CDs in the broader field of nanotechnology, their development history, classification, synthesis, and potential for tumor treatment. Especially in the treatment of cancer, CDs can not only participate in photodynamic therapy, photothermal therapy, sonodynamic therapy, chemodynamic therapy, and chemotherapy, but also in multi-modal combination therapy. Here, we hope to provide some insights for further research.
- 1 April 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (1) , e242671
Intravenous Thrombolysis before Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Medium Vessel Occlusion
- 1 April 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 315 (1) , e242671
Intravenous Thrombolysis before Mechanical Thrombectomy in Patients with Acute Ischemic Stroke Due to Medium Vessel Occlusion
- 10 December 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (1) , 133-139
Efficacy and safety outcomes of endovascular versus best medical treatment in posterior cerebral artery occlusion stroke
Background The management of acute ischemic stroke due to isolated posterior cerebral artery occlusion (iPCAO) remains a topic of debate. This study investigates the efficacy and safety of endovascular treatment (EVT) versus best medical treatment (BMT) in patients with iPCAO. Methods A systematic search was conducted across electronic databases including PubMed, Embase, and the Cochrane Library. Controlled studies comparing EVT and BMT in patients with iPCAO were selected. The primary efficacy outcome assessed was excellent outcome, defined as a modified Rankin Scale (mRS) score of 0–1. The primary safety outcome was symptomatic intracranial hemorrhage (sICH). Secondary outcomes included functional independence (mRS 0–2), early neurological improvement (ENI), and mortality rates. Statistical analyses were conducted using random effects models. Results Eleven retrospective cohort studies involving 1811 patients with EVT and 2871 patients with BMT were analyzed. Compared with BMT, EVT was associated with a higher likelihood of an excellent outcome (adjusted OR (aOR) 1.33, 95% CI 1.14 to 1.54) and ENI (aOR 1.66, 95% CI 1.39 to 1.98), but no significant difference in functional independence (aOR 1.02, 95% CI 0.88 to 1.18). Compared with BMT, EVT may not be associated with an increased risk of sICH in patients with iPCAO (aOR 1.34, 95% CI 0.60 to 3.02) or mortality (aOR 1.31, 95% CI 0.83 to 2.08), although heterogeneity was high. Conclusions EVT may improve the likelihood of an excellent outcome and ENI in patients with iPCAO. However, the potential risks of sICH and mortality warrant consideration. Randomized trials are required to establish the definitive efficacy and safety of EVT in this patient population.
- 10 December 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (1) , 133-139
Efficacy and safety outcomes of endovascular versus best medical treatment in posterior cerebral artery occlusion stroke
Background The management of acute ischemic stroke due to isolated posterior cerebral artery occlusion (iPCAO) remains a topic of debate. This study investigates the efficacy and safety of endovascular treatment (EVT) versus best medical treatment (BMT) in patients with iPCAO. Methods A systematic search was conducted across electronic databases including PubMed, Embase, and the Cochrane Library. Controlled studies comparing EVT and BMT in patients with iPCAO were selected. The primary efficacy outcome assessed was excellent outcome, defined as a modified Rankin Scale (mRS) score of 0–1. The primary safety outcome was symptomatic intracranial hemorrhage (sICH). Secondary outcomes included functional independence (mRS 0–2), early neurological improvement (ENI), and mortality rates. Statistical analyses were conducted using random effects models. Results Eleven retrospective cohort studies involving 1811 patients with EVT and 2871 patients with BMT were analyzed. Compared with BMT, EVT was associated with a higher likelihood of an excellent outcome (adjusted OR (aOR) 1.33, 95% CI 1.14 to 1.54) and ENI (aOR 1.66, 95% CI 1.39 to 1.98), but no significant difference in functional independence (aOR 1.02, 95% CI 0.88 to 1.18). Compared with BMT, EVT may not be associated with an increased risk of sICH in patients with iPCAO (aOR 1.34, 95% CI 0.60 to 3.02) or mortality (aOR 1.31, 95% CI 0.83 to 2.08), although heterogeneity was high. Conclusions EVT may improve the likelihood of an excellent outcome and ENI in patients with iPCAO. However, the potential risks of sICH and mortality warrant consideration. Randomized trials are required to establish the definitive efficacy and safety of EVT in this patient population.
- 8 August 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (e2) , e222-e230
Bridging thrombolysis before endovascular therapy is associated with better outcomes in patients with large infarction core
Background This study investigates the efficacy and safety of bridging intravenous thrombolysis (IVT) before endovascular therapy (EVT) compared with EVT alone in patients with large infarction core. Methods We conducted a comprehensive search of PubMed, EMBASE, and the Cochrane Library from January 2015 to June 2024. Included studies involved patients with acute ischemic stroke with an Alberta Stroke Program Early CT Score of ≤5 or an ischemic core volume of ≥50 mL. Studies were required to provide either 90-day modified Rankin Scale (mRS) score, reperfusion, symptomatic intracranial hemorrhage (sICH), or 90-day mortality. Results Nine observational studies with 2641 patients were analyzed. The IVT+EVT group had a higher rate of 90-day functional independence (mRS 0–2; OR 1.56, 95% CI 1.31 to 1.87; adjusted OR (aOR) 1.43, 95% CI 1.21 to 1.68) and 90-day functional outcome (mRS 0–3; OR 1.34, 95% CI 1.11 to 1.62; aOR 1.18, 95% CI 1.02 to 1.37) compared with EVT alone. There was no significant difference in successful reperfusion (OR 1.01, 95% CI 0.62 to 1.64; aOR 1.07, 95% CI 0.74 to 1.54) and 90-day mortality (OR 0.86, 95% CI 0.73 to 1.02; aOR 0.89, 95% CI 0.77 to 1.04) between the two groups. Moreover, patients who received IVT+EVT had a higher rate of sICH (OR 1.30, 95% CI 1.03 to 1.64; aOR 2.21, 95% CI 1.22 to 4.01). Conclusions In patients with large infarction core, bridging IVT before EVT is associated with favorable functional outcomes compared with EVT, even though bridging therapy entails a higher risk of sICH. Further trials are needed to confirm these findings.
- 8 August 2024
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (e2) , e222-e230
Bridging thrombolysis before endovascular therapy is associated with better outcomes in patients with large infarction core
Background This study investigates the efficacy and safety of bridging intravenous thrombolysis (IVT) before endovascular therapy (EVT) compared with EVT alone in patients with large infarction core. Methods We conducted a comprehensive search of PubMed, EMBASE, and the Cochrane Library from January 2015 to June 2024. Included studies involved patients with acute ischemic stroke with an Alberta Stroke Program Early CT Score of ≤5 or an ischemic core volume of ≥50 mL. Studies were required to provide either 90-day modified Rankin Scale (mRS) score, reperfusion, symptomatic intracranial hemorrhage (sICH), or 90-day mortality. Results Nine observational studies with 2641 patients were analyzed. The IVT+EVT group had a higher rate of 90-day functional independence (mRS 0–2; OR 1.56, 95% CI 1.31 to 1.87; adjusted OR (aOR) 1.43, 95% CI 1.21 to 1.68) and 90-day functional outcome (mRS 0–3; OR 1.34, 95% CI 1.11 to 1.62; aOR 1.18, 95% CI 1.02 to 1.37) compared with EVT alone. There was no significant difference in successful reperfusion (OR 1.01, 95% CI 0.62 to 1.64; aOR 1.07, 95% CI 0.74 to 1.54) and 90-day mortality (OR 0.86, 95% CI 0.73 to 1.02; aOR 0.89, 95% CI 0.77 to 1.04) between the two groups. Moreover, patients who received IVT+EVT had a higher rate of sICH (OR 1.30, 95% CI 1.03 to 1.64; aOR 2.21, 95% CI 1.22 to 4.01). Conclusions In patients with large infarction core, bridging IVT before EVT is associated with favorable functional outcomes compared with EVT, even though bridging therapy entails a higher risk of sICH. Further trials are needed to confirm these findings.